重组人红细胞生成素治疗20例含顺铂化疗诱发的贫血

Recombinant human erythropoietin in the treatment of cisplatin-based-chemotherapy-induced a-nemia

目的:研究重组人红细胞生成素(rHuEPO)治疗肿瘤化疗诱发贫血的疗效及安全性。方法:采用随机的方法将41例肿瘤伴化疗诱发贫血的患者分为EPO治疗组和对照组,两组具有可比性,治疗组给予EPO 150 u/(kg·次),5次/周,皮下注射,连续用药8周,并于用药后1周开始加用铁剂速力菲100 mg口服,3次/d。对照组不给予EPO,其他治疗同治疗组。观察EPO对血红蛋白水平、输血情况及生活质量的影响及副反应。结果:①治疗组血红蛋白水平治疗后平均提高23.0g/L,而对照组反而下降10.7g/L(P<0.001),治疗组生活质量KPS评分治疗后平均提高6.50,而对照组反而下降9.30(P<0.001)②治疗组与对照组在治疗后的输血率和输血量相比较差异无显著性③应用重组人红细胞生成素的副反应少,耐受性好。结论:rHuEPO对肿瘤化疗诱发贫血是一个安全有效的用药,不仅能提高Hb水平,而且能改善患者生活质量,值得我们进一步推广和扩大应用。

Purpose:To study the efficiency and the safety of recombinant human erythropoietin (rHuEPO) in the treatment of chemotherapy-induced anemia.Methods:41 tumor patients were randomized into two groups:EPO-treatment group and control group,in order to observe the changes of the haemoglobin level,transfusion requirement and quality of life for the two groups respectively.Results:①the increase of haemoglobin level and the quality of life in the EPO-treat- ment group compared with that in the control group was statistically significant.②the reduction of transfusion requirement in the EPO-treatment group compared with that in the control group was not statistically significant.③treatment of EPO has few side-effects and a good tolerance.Conclusions:rHuEPO in the treatment of chemotherapy-induced anemia is effec- tive and safe.Not only can it increase the haemoglobin level but also improve the quality of life for the patients,so it should be used widely.